CAR-T (Allogeneic)
Memory NK (Allogeneic)
-- WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors -- --WU-NK-101 exhibited robust trafficking, intra-tumor infiltration,…
-- Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell…
SAINT LOUIS, MO and SAN DIEGO, CA, November 10, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…
Wugen is a clinical-stage biotechnology company
Cellular therapies originating from healthy donors
Come join our growing teams in San Diego and St. Louis